The decision should reduce uncertainty in the field of molecular diagnostics.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
A biomarker could cut the trial-and-error of finding a patient's best therapy.
From millions of random mutations, scientists identify a virus that could make gene therapy for inherited retinal diseases safer and more effective.
A common framework for analyzing and sharing genomic information could speed medical progress.
Mind-control optogenetics experiments in mice give new clarity to the neural circuitry that underlines repetitive behaviors.
A Boston startup wants to bring smart analytics to critical care in order to help doctors spot and treat at-risk patients.
A neuroscientist is getting a brain scan twice every week for a year to try to see how neural networks behave over time.
A large genetic study finds gene variants with a subtle effect on scholastic achievement.
A French company is preparing to test a complex artificial heart that combines biology with machinery.
In your DNA are clues to your health, your ancestry, and maybe even your purchasing preferences.